Heart transplant patients with
hypertrophic cardiomyopathy have high survival rates
Transplant surgery to correct the most common type of
genetic heart disease yields similar short-term and potentially greater long-term
survival rates as transplant surgery for other heart diseases, according to research
reported in Circulation: Heart Failure, an American Heart Association journal.
Researchers found similar survival rates one year after heart transplant surgery
between hypertrophic cardiomyopathy (HCM) patients (85 percent) and those with
other kinds of heart disease (82 percent). Five years post-surgery, survival rates
began to diverge with 75 percent of HCM and 70 percent of other patients surviving.
At the 10-year mark, survival rates in both groups dropped, although they remained
significantly higher in the HCM patients (61 percent) than in those with other
heart diseases (49 percent).
“Patients with this disease who are undergoing transplant can expect reasonable
long-term survival rates," said Martin S. Maron, M.D., lead author and assistant
professor of medicine, director of the Hypertrophic Cardiomyopathy Center, and
co-director of Advanced Cardiac Imaging at Tufts Medical Center in Boston, Mass.
“That’s a crucial clinical message for this small but important subgroup of patients."
Investigators used the United Network of Organ Sharing Registry, a nationwide
database of all U.S. transplant patients, to analyze 26,706 adult patients’ clinical
and survival characteristics. HCM patients comprise about 1 percent of all U.S.
heart transplant cases. Yet, the survival rate is comparable to surgeries for
other reasons.
Study participants were mostly white (81 percent) and male (79 percent), average
age 52. HCM patients, however, tended to be younger, average age 43, and more
than half were women. Nearly one-third (31 percent) of participants reported smoking,
although this rate was much lower among those with HCM (17 percent). All had received
a heart transplant between January 1990 and December 2004.
Co-authors are Benjamin M. Kalsmith, M.D.; James E. Udelson, M.D.; Wenjun Li,
Ph.D. and David DeNofrio, M.D.
|